“Our multiple presentations at ESGCT demonstrate uniQure’s continued leadership in advancing important research within the field of gene therapy, as well as highlight our industry-leading expertise in AAV gene therapy manufacturing,” stated
Specific details on uniQure’s presentations taking place at ESGCT include:
- Invited Talk Title: Update on
U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
Presenter:Richard Porter , Chief Business and Scientific Officer, uniQure
Session Title and Location: CNS & sensory diseases II, Session 10a, Shed 2A
Date and Time:Friday, October 27 , 8:30 a.m. GMT+2
- Title: Gene therapy for C9ORF72-ALS reduces RNA toxicity and ameliorates behavioral phenotype in ALS mouse model
Presenter:Vanessa Zancanella , Sr.Scientist Global Research , uniQure
Session Title and Location: CNS & sensory diseases I, Session 2c,Maison de la Poste
Date and Time:Tuesday, October 24 , 17:00 – 19:00 GMT+2
- Title: Pivotal safety studies for AMT-260, a novel AAV9-dual microRNA-based vector targeting GRIK2 for the treatment of temporal lobe epilepsy (Poster #433)
Presenter:Nick Pearson , Sr. Director Toxicology & Translational Safety, Non-Clinical, uniQure
Poster Session Date and Time:Wednesday, October 25 , 17:00 – 18:15,Thursday, October 26 , 20:30 – 21:30 GMT+2
- Title: Production of low cross-packaging AAV capsid libraries in insect cells (Poster #166)
Presenter:Bas Bosma , Scientific Leader, Technology Innovation, uniQure
Poster Session Date and Time:Wednesday, October 25 , 18:15 – 19:30,Thursday October 26 , 19:30 – 20:30 GMT+2
- Title: Multiplexed comparison of rationally-designed AAV CNS capsids in vivo (Poster #181)
Presenter:Elena Pimentel , Scientist, Technology Innovation, uniQure
Poster Session Date and Time:Wednesday, October 25 , 17:00 – 18:15,Thursday, October 26 , 20:30 – 21:30 GMT+2
- Title: Silence and replace as potential treatment for Alzheimer Disease: in concert lowering toxic APOE and augmenting protective APOE (Poster #049)
Presenter:Amila Zuko , Scientist,Global Research , uniQure
Poster Session Date and Time:Wednesday, October 25 , 17:00 – 18:15,Thursday, October 26 , 20:30 – 21:30 GMT+2
- Title: Gene therapy for synucleinopathies: Combining vectorized antibody and miRNA-mediated lowering strategies (Poster #430)
Presenter:Kim Wolzak , Jr. Scientist,Global Research , uniQure
Poster Session Date and Time:Wednesday, October 25 , 18:15-19:30,Thursday, October 26 , 19:30-20:30 GMT+2
- Title: Alpha-synuclein lowering and rescue of motor phenotype by miRNA-based AAV gene therapy in an in vivo Parkinson’s disease rat model (Poster #420)
Presenter: Rhodé van Westen Erbrink, Scientist,Global Research , uniQure
Poster Session Date and Time:Wednesday, October 25 , 18:15-19:30,Thursday, October 26 , 19:30-20:30 GMT+2
- Title: How uniQure’s modular platform approach drives continuous innovation in AAV gene therapy development and manufacturing (Poster #329)
Presenter:Erich Ehlert , Director –Process Development – Chemistry, Manufacturing and Controls, uniQure
Poster Session Date and Time:Wednesday, October 25 , 17:00-18:15,Thursday, October 26 , 20:30-21:30 GMT+2
- Title: Accelerating process development by establishing drug substance development platform (Poster #191)
Presenter:Giorgio Rainone , Bioprocess Technologist,Drug Substance Development , uniQure
Poster Session Date and Time:Wednesday, October 25 , 17:00-18:15,Thursday, October 26 , 20:30-21:30 GMT+2
- Title: High-throughput process development in rAAV drug substance manufacturing (Poster #308)
Presenter:Yang Jiang , Associate Director,Drug Substance Development , uniQure
Poster Session Date and Time:Wednesday, October 25 , 18:15-19:30,Thursday, October 26 , 19:30-20:30 GMT+2
- Title: Platform development for AAV manufacturing with the Baculovirus Expression Vector System (BEVS) (Poster #193)
Presenter: Zandra Félix Garza, Project Manager- BPU – Cells, Seeds and Research Supply, uniQure
Poster Session Date and Time:Wednesday, October 25 , 17:00-18:15,Thursday, October 26 , 20:30-21:30 GMT+2
About uniQure
uniQure’s mission is to reimagine the future of medicine by delivering innovative cures that transform lives. The recent approvals of our gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. We are now leveraging our modular and validated technology and manufacturing platform to advance a pipeline of proprietary gene therapies for the treatment of patients with
uniQure Contacts:
FOR INVESTORS: Direct: 617-306-9137 Mobile: 617-306-9137 c.russo@uniQure.com | FOR MEDIA: Direct: 339-970-7558 Mobile:339-223-8541 t.malone@uniQure.com |
Source: uniQure Inc.
2023 GlobeNewswire, Inc., source